Rhythm Pharmaceuticals Stock Price, News & Analysis (NASDAQ:RYTM)

$27.61 +1.55 (+5.95 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$27.61
Today's Range$25.69 - $27.61
52-Week Range$21.38 - $33.81
Volume41,744 shs
Average Volume67,651 shs
Market Capitalization$711.03 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Rhythm Pharmaceuticals (NASDAQ:RYTM)

Rhythm Pharmaceuticals logoRhythm Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity. Setmelanotide serves as replacement therapy for the treatment of melanocortin-4, or MC4, pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity. The Company also focused on obesity related to six single gene-related, or monogenic, MC4 pathway deficiencies pro-opiomelanocortin, or POMC, leptin receptor, or LepR, Bardet-Biedl syndrome, Alstrom syndrome, POMC heterozygous, and POMC epigenetic disorders.

Receive RYTM News and Ratings via Email

Sign-up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RYTM
CUSIPN/A
Phone857-264-4280

Debt

Debt-to-Equity RatioN/A
Current Ratio5.87%
Quick Ratio5.87%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees15
Outstanding Shares27,280,000

Rhythm Pharmaceuticals (NASDAQ:RYTM) Frequently Asked Questions

What is Rhythm Pharmaceuticals' stock symbol?

Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."

How were Rhythm Pharmaceuticals' earnings last quarter?

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) issued its quarterly earnings results on Tuesday, November, 14th. The company reported ($1.78) EPS for the quarter, missing the consensus estimate of ($0.40) by $1.38. View Rhythm Pharmaceuticals' Earnings History.

Where is Rhythm Pharmaceuticals' stock going? Where will Rhythm Pharmaceuticals' stock price be in 2018?

4 brokerages have issued 1-year price targets for Rhythm Pharmaceuticals' stock. Their predictions range from $23.00 to $40.00. On average, they expect Rhythm Pharmaceuticals' share price to reach $31.25 in the next year. View Analyst Ratings for Rhythm Pharmaceuticals.

What are Wall Street analysts saying about Rhythm Pharmaceuticals stock?

Here are some recent quotes from research analysts about Rhythm Pharmaceuticals stock:

  • 1. Cowen Inc analysts commented, "Rhythm released Q3 financials this morning, following the presentation of promising." (11/14/2017)
  • 2. Needham & Company LLC analysts commented, "Rhythm reported 3Q17 financial results and we spoke w/ mgmt for an update. Enrollment in Phase 3 setmelanotide trial in POMC Deficiency is still expected to be completed by YE17. We assume top-line results in early 2019 (unch) and continue to expect a positive outcome. Mgmt also reiterated guidance for intiation of Phase 3 setmelanotide trial in LepR Deficiency by YE17. Data in a small number of patients with POMC or LepR Deficiency were remarkably strong and are the basis for our enthusiasm for the drug and the stock. We await data from Phase 2 trials in Alstrom Syndrome and POMC Epigenetic/ Heterozygous mutation patients in early 2018. A favorable outcome would add meaningfully to peak sales potential. BUY." (11/14/2017)

Who are some of Rhythm Pharmaceuticals' key competitors?

Who are Rhythm Pharmaceuticals' key executives?

Rhythm Pharmaceuticals' management team includes the folowing people:

  • David P. Meeker M.D., Chairman of the Board (Age 63)
  • Keith Gottesdiener M.D., President, Chief Executive Officer, Director (Age 63)
  • Hunter C. Smith, Chief Financial Officer, Treasurer (Age 49)
  • Lex H.T. Van der Ploeg Ph.D., Chief Scientific Officer (Age 63)
  • Nithya Desikan, Chief Commercial Officer (Age 38)
  • Fred T. Fiedorek M.D., Chief Medical Officer (Age 62)
  • Neil Exter, Independent Director (Age 58)
  • Todd Foley, Independent Director (Age 45)
  • Christophe R. Jean, Independent Director (Age 61)
  • Edward T. Mathers, Independent Director (Age 57)

When did Rhythm Pharmaceuticals IPO?

(RYTM) raised $100 million in an initial public offering on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager.

When does the company's lock-up period expire?

Rhythm Pharmaceuticals' lock-up period expires on Tuesday, April 3rd. Rhythm Pharmaceuticals had issued 7,050,000 shares in its public offering on October 5th. The total size of the offering was $119,850,000 based on an initial share price of $17.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.

Who owns Rhythm Pharmaceuticals stock?

Rhythm Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include MPM Asset Management LLC (9.88%), Perceptive Advisors LLC (2.73%), ArrowMark Colorado Holdings LLC (1.70%), BlackRock Inc. (1.32%), Franklin Resources Inc. (0.91%) and Citadel Advisors LLC (0.74%). Company insiders that own Rhythm Pharmaceuticals stock include Bros Advisors Lp Baker, David P Meeker, James E Flynn and SA Ipsen. View Institutional Ownership Trends for Rhythm Pharmaceuticals.

Who bought Rhythm Pharmaceuticals stock? Who is buying Rhythm Pharmaceuticals stock?

Rhythm Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including MPM Asset Management LLC, Perceptive Advisors LLC, ArrowMark Colorado Holdings LLC, BlackRock Inc., Franklin Resources Inc., Citadel Advisors LLC, Geode Capital Management LLC and Rock Springs Capital Management LP. Company insiders that have bought Rhythm Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, David P Meeker, James E Flynn and SA Ipsen. View Insider Buying and Selling for Rhythm Pharmaceuticals.

How do I buy Rhythm Pharmaceuticals stock?

Shares of Rhythm Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Rhythm Pharmaceuticals' stock price today?

One share of Rhythm Pharmaceuticals stock can currently be purchased for approximately $27.61.

How big of a company is Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals has a market capitalization of $711.03 million. Rhythm Pharmaceuticals employs 15 workers across the globe.

How can I contact Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals' mailing address is 500 BOYLSTON STREET 11TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-264-4280 or via email at [email protected]


MarketBeat Community Rating for Rhythm Pharmaceuticals (RYTM)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  55 (Vote Outperform)
Underperform Votes:  43 (Vote Underperform)
Total Votes:  98
MarketBeat's community ratings are surveys of what our community members think about Rhythm Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Rhythm Pharmaceuticals (NASDAQ:RYTM) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score: 2.752.752.75N/A
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $31.25$31.25$31.25N/A
Price Target Upside: 22.74% upside22.74% upside22.74% upsideN/A

Rhythm Pharmaceuticals (NASDAQ:RYTM) Consensus Price Target History

Price Target History for Rhythm Pharmaceuticals (NASDAQ:RYTM)

Rhythm Pharmaceuticals (NASDAQ:RYTM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/14/2017CowenReiterated RatingBuy$40.00N/AView Rating Details
11/14/2017Needham & Company LLCReiterated RatingBuy$32.00N/AView Rating Details
10/30/2017Morgan StanleyInitiated CoverageEqual Weight$23.00N/AView Rating Details
10/30/2017Bank of AmericaInitiated CoverageBuy$30.00N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Rhythm Pharmaceuticals (NASDAQ:RYTM) Earnings History and Estimates Chart

Earnings by Quarter for Rhythm Pharmaceuticals (NASDAQ:RYTM)

Rhythm Pharmaceuticals (NASDAQ RYTM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017Q3 2017($0.40)($1.78)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Rhythm Pharmaceuticals (NASDAQ:RYTM) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.63 EPS
Next Year EPS Consensus Estimate: $-2.05 EPS

Dividends

Dividend History for Rhythm Pharmaceuticals (NASDAQ:RYTM)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Rhythm Pharmaceuticals (NASDAQ RYTM) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 56.47%
Insider Trades by Quarter for Rhythm Pharmaceuticals (NASDAQ:RYTM)
Institutional Ownership by Quarter for Rhythm Pharmaceuticals (NASDAQ:RYTM)

Rhythm Pharmaceuticals (NASDAQ RYTM) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/10/2017David P MeekerDirectorBuy25,000$17.00$425,000.00View SEC Filing  
10/10/2017James E FlynnInsiderBuy355,000$17.00$6,035,000.00View SEC Filing  
10/10/2017S.A. IpsenMajor ShareholderBuy20,000$17.00$340,000.00View SEC Filing  
10/5/2017Bros. Advisors Lp BakerInsiderBuy885,000$17.00$15,045,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Rhythm Pharmaceuticals (NASDAQ RYTM) News Headlines

Source:
DateHeadline
Analysts Anticipate Rhythm Pharmaceuticals Inc (RYTM) to Announce ($0.55) Earnings Per ShareAnalysts Anticipate Rhythm Pharmaceuticals Inc (RYTM) to Announce ($0.55) Earnings Per Share
www.americanbankingnews.com - February 22 at 5:10 AM
 Rhythm Pharmaceuticals Inc (RYTM) Given $31.25 Consensus Price Target by Brokerages Rhythm Pharmaceuticals Inc (RYTM) Given $31.25 Consensus Price Target by Brokerages
www.americanbankingnews.com - February 18 at 5:24 AM
 Brokerages Anticipate Rhythm Pharmaceuticals Inc (RYTM) to Post -$0.55 EPS Brokerages Anticipate Rhythm Pharmaceuticals Inc (RYTM) to Post -$0.55 EPS
www.americanbankingnews.com - February 14 at 3:18 AM
Rhythm Pharmaceuticals (RYTM) Lowered to Hold at BidaskClubRhythm Pharmaceuticals (RYTM) Lowered to Hold at BidaskClub
www.americanbankingnews.com - February 4 at 6:22 AM
Zacks: Rhythm Pharmaceuticals Inc (RYTM) Receives Average Rating of "Buy" from AnalystsZacks: Rhythm Pharmaceuticals Inc (RYTM) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - February 2 at 7:22 PM
Rhythm Pharmaceuticals (RYTM) Rating Increased to Buy at BidaskClubRhythm Pharmaceuticals (RYTM) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - January 29 at 10:42 PM
Analysts Anticipate Rhythm Pharmaceuticals Inc (RYTM) to Post ($0.55) Earnings Per ShareAnalysts Anticipate Rhythm Pharmaceuticals Inc (RYTM) to Post ($0.55) Earnings Per Share
www.americanbankingnews.com - January 25 at 11:41 AM
Critical Analysis: Rhythm Pharmaceuticals (RYTM) versus The CompetitionCritical Analysis: Rhythm Pharmaceuticals (RYTM) versus The Competition
www.americanbankingnews.com - January 10 at 11:14 PM
Zacks: Rhythm Pharmaceuticals Inc (RYTM) Receives Average Recommendation of "Buy" from AnalystsZacks: Rhythm Pharmaceuticals Inc (RYTM) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 9 at 9:46 PM
WuXi NextCODE Artificial Intelligence Used to Advance Precision Therapy for Rare Genetic Disorders of ObesityWuXi NextCODE Artificial Intelligence Used to Advance Precision Therapy for Rare Genetic Disorders of Obesity
finance.yahoo.com - January 9 at 6:11 PM
Rhythm Pharmaceuticals Announces Progress in Clinical Development of Setmelanotide for Treatment of Rare Genetic Disorders of ObesityRhythm Pharmaceuticals Announces Progress in Clinical Development of Setmelanotide for Treatment of Rare Genetic Disorders of Obesity
finance.yahoo.com - January 4 at 8:49 AM
Zacks: Rhythm Pharmaceuticals, Inc. (RYTM) Given Consensus Recommendation of "Buy" by AnalystsZacks: Rhythm Pharmaceuticals, Inc. (RYTM) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - January 2 at 8:02 AM
BidaskClub Downgrades Rhythm Pharmaceuticals (RYTM) to HoldBidaskClub Downgrades Rhythm Pharmaceuticals (RYTM) to Hold
www.americanbankingnews.com - December 29 at 6:32 AM
Zacks: Rhythm Pharmaceuticals, Inc. (RYTM) Receives Average Recommendation of "Buy" from BrokeragesZacks: Rhythm Pharmaceuticals, Inc. (RYTM) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - December 15 at 5:52 AM
 Brokerages Set $31.25 Target Price for Rhythm Pharmaceuticals, Inc. (RYTM) Brokerages Set $31.25 Target Price for Rhythm Pharmaceuticals, Inc. (RYTM)
www.americanbankingnews.com - November 30 at 3:12 AM
Rhythm Pharmaceuticals, Inc. (RYTM) Announces  Earnings ResultsRhythm Pharmaceuticals, Inc. (RYTM) Announces Earnings Results
www.americanbankingnews.com - November 15 at 1:03 PM
 Rhythm Pharmaceuticals, Inc. (RYTM) Given Consensus Recommendation of "Buy" by Analysts Rhythm Pharmaceuticals, Inc. (RYTM) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - November 15 at 9:47 AM
General Electric Cuts 2018 EPS Target, Slashes Dividend - Presented by: The Aol. On NetworkGeneral Electric Cuts 2018 EPS Target, Slashes Dividend - Presented by: The Aol. On Network
www.nasdaq.com - November 15 at 7:54 AM
Rhythm Pharmaceuticals Reports Third Quarter 2017 Financial ResultsRhythm Pharmaceuticals Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 15 at 7:54 AM
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Rating Reaffirmed by Needham & Company LLCRhythm Pharmaceuticals, Inc. (RYTM) Stock Rating Reaffirmed by Needham & Company LLC
www.americanbankingnews.com - November 14 at 10:26 PM
Rhythm Pharmaceuticals, Inc. (RYTM) Given "Buy" Rating at Cowen and CompanyRhythm Pharmaceuticals, Inc. (RYTM) Given "Buy" Rating at Cowen and Company
www.americanbankingnews.com - November 14 at 10:26 PM
Torque, a Flagship Pioneering Company, Launches Platform to Develop a New Class of Deep-Primed™ Immune Cell Therapies, Financed with $25M Series A and Led by a Veteran Management TeamTorque, a Flagship Pioneering Company, Launches Platform to Develop a New Class of Deep-Primed™ Immune Cell Therapies, Financed with $25M Series A and Led by a Veteran Management Team
finance.yahoo.com - November 14 at 7:32 AM
Rhythm Pharmaceuticals Breaks Through - Bhavneesh Sharmas Idea Of The MonthRhythm Pharmaceuticals Breaks Through - Bhavneesh Sharma's Idea Of The Month
seekingalpha.com - November 7 at 9:45 AM
Rhythm Pharmaceuticals, Inc.s Quiet Period To End  on November 14th (NASDAQ:RYTM)Rhythm Pharmaceuticals, Inc.'s Quiet Period To End on November 14th (NASDAQ:RYTM)
www.americanbankingnews.com - November 7 at 1:26 AM
9 Speculative Analyst Stocks With Projected Upside of 50% to 200%9 Speculative Analyst Stocks With Projected Upside of 50% to 200%
247wallst.com - November 4 at 6:13 PM
Rhythm Pharmaceuticals: Todays Data Is Just The BeginningRhythm Pharmaceuticals: Today's Data Is Just The Beginning
seekingalpha.com - November 1 at 3:26 PM
Zacks: Analysts Set $31.00 Price Target for Rhythm Pharmaceuticals, Inc. (RYTM)Zacks: Analysts Set $31.00 Price Target for Rhythm Pharmaceuticals, Inc. (RYTM)
www.americanbankingnews.com - October 31 at 10:22 AM
Rhythm Announces Preliminary Data from Phase 2 Study of Setmelanotide for Treatment of Bardet-Biedl SyndromeRhythm Announces Preliminary Data from Phase 2 Study of Setmelanotide for Treatment of Bardet-Biedl Syndrome
finance.yahoo.com - October 31 at 9:00 AM
Morgan Stanley Initiates Coverage on Rhythm Pharmaceuticals, Inc. (RYTM)Morgan Stanley Initiates Coverage on Rhythm Pharmaceuticals, Inc. (RYTM)
www.americanbankingnews.com - October 30 at 9:19 AM
Rhythm Pharmaceuticals, Inc. (RYTM) Now Covered by Analysts at Needham & Company LLCRhythm Pharmaceuticals, Inc. (RYTM) Now Covered by Analysts at Needham & Company LLC
www.americanbankingnews.com - October 30 at 8:09 AM
Rhythm Pharmaceuticals, Inc. (RYTM) Earns Buy Rating from Analysts at Bank of America CorporationRhythm Pharmaceuticals, Inc. (RYTM) Earns Buy Rating from Analysts at Bank of America Corporation
www.americanbankingnews.com - October 30 at 8:08 AM
Orphan Disease IPO, Rhythm Pharmaceuticals: Initiating Coverage With Buy Rating And $34 Price Target (40% Upside)Orphan Disease IPO, Rhythm Pharmaceuticals: Initiating Coverage With Buy Rating And $34 Price Target (40% Upside)
seekingalpha.com - October 27 at 3:45 PM
Rhythm Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesRhythm Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - October 11 at 7:22 AM
This Company Gained 76% in its IPO -- and It Isn't Even a Tech CompanyThis Company Gained 76% in its IPO -- and It Isn't Even a Tech Company
finance.yahoo.com - October 11 at 7:22 AM
Insider Buying: Rhythm Pharmaceuticals Inc (RYTM) Director Buys 25,000 Shares of StockInsider Buying: Rhythm Pharmaceuticals Inc (RYTM) Director Buys 25,000 Shares of Stock
www.americanbankingnews.com - October 10 at 7:38 PM
Insider Buying: Rhythm Pharmaceuticals Inc (RYTM) Major Shareholder Purchases 20,000 Shares of StockInsider Buying: Rhythm Pharmaceuticals Inc (RYTM) Major Shareholder Purchases 20,000 Shares of Stock
www.americanbankingnews.com - October 10 at 7:38 PM
Rhythm Pharmaceuticals Inc (RYTM) Insider Buys $6,035,000.00 in StockRhythm Pharmaceuticals Inc (RYTM) Insider Buys $6,035,000.00 in Stock
www.americanbankingnews.com - October 10 at 1:32 PM
IPO News This Week: Online Auto Marketplace, CarGurus, Tops the ListIPO News This Week: Online Auto Marketplace, CarGurus, Tops the List
finance.yahoo.com - October 9 at 2:16 AM
Rhythm Pharmaceutical (RYTM) IPO Opens Up 37%Rhythm Pharmaceutical (RYTM) IPO Opens Up 37%
www.streetinsider.com - October 6 at 8:52 PM
Switch Keeps Recent IPO Market Momentum GoingSwitch Keeps Recent IPO Market Momentum Going
finance.yahoo.com - October 6 at 8:52 PM
Bros. Advisors Lp Baker Purchases 885,000 Shares of Rhythm Pharmaceuticals Inc (RYTM) StockBros. Advisors Lp Baker Purchases 885,000 Shares of Rhythm Pharmaceuticals Inc (RYTM) Stock
www.americanbankingnews.com - October 6 at 7:24 PM
Rhythm Pharmaceuticals (RYTM) Plans to Raise $100 Million in October 5th IPORhythm Pharmaceuticals (RYTM) Plans to Raise $100 Million in October 5th IPO
www.americanbankingnews.com - September 27 at 1:18 AM

SEC Filings

Rhythm Pharmaceuticals (NASDAQ:RYTM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Rhythm Pharmaceuticals (NASDAQ:RYTM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Rhythm Pharmaceuticals (NASDAQ RYTM) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.